Table 1

Patient characteristics

 Overall (n=43)Small LGE (n=21)Large LGE (n=22)p Value
Small vs large
Age (years)59±1059±1260±90.798
Male, n (%)15 (35)6 (29)9 (41)0.396
Body Mass Index (kg/m2)22.3±3.122.7±3.021.9±3.30.417
Systolic blood pressure (mm Hg)123±18126±17120±180.250
Diastolic blood pressure (mm Hg)72±1271±1173±130.642
NYHA functional class0.875
 I, n (%)7 (16)4 (19)3 (14)
 II, n (%)27 (63)13 (62)14 (64)
 III, n (%)9 (21)4 (19)5 (23)
 IV, n (%)0 (0)0 (0)0 (0)
Organ involvement
 Lung, n (%)9 (21)4 (19)5 (23)0.767
 Eye, n (%)3 (7)2 (10)1 (5)0.522
 Skin, n (%)2 (5)1 (5)1 (5)0.973
Laboratory results at the beginning of steroid therapy
 White blood cell count (/μL)5701±15875428±12885961±18200.276
 Haemoglobin (g/dL)13.4±1.513.3±1.613.4±1.30.709
 Serum creatinine (mg/dL)0.8±0.20.8±0.20.8±0.20.845
 eGFR (mL/min/1.73m2)55±1554±1456±160.640
 Albumin (g/dL)4.1±0.34.0±0.34.1±0.30.573
 Calcium (mg/dL)9.5±0.49.4±0.29.6±0.60.311
 BNP (pg/mL)293±233216±174368±2610.031
 ACE (U/L)14.7±8.415.0±9.214.4±7.60.843
 Lysozyme (μg/mL)8.0±4.17.2±3.28.9±5.00.222
Medications at the beginning of steroid therapy
 β blockers, n (%)18 (42)8 (38)10 (45)0.625
 ACE inhibitors, n (%)17 (40)7 (33)10 (45)0.416
 ARB, n (%)9 (21)4 (19)5 (23)0.767
 Diuretics, n (%)23 (53)9 (43)14 (64)0.172
 Antiarrhythmic agents, n (%)9 (21)5 (24)4 (18)0.650
Implanted devices at the beginning of steroid therapy
 Pacemaker, n (%)7 (16)5 (24)2 (9)0.191
 Implantable cardioverter defibrillator, n (%)7 (16)3 (14)4 (18)0.729
 Cardiac resynchronisation therapy, n (%)2 (5)0 (0)2 (9)0.157
Echocardiographic analysis
 LVEF (%)41±1045±1136±60.001
 LV diastolic dimension (mm)57±852±661±8<0.001
 LV systolic dimension (mm)44±939±849±7<0.001
 LV end-diastolic volume index (mL/m2)111±3892±27130±38<0.001
 LV end-systolic volume index (mL/m2)68±3152±2284±30<0.001
CMR analysis
 LVEF (%)38±1243±1232±100.002
 LV end-diastolic volume index (mL/m2)112±4292±27132±450.001
 LV end-systolic volume index (mL/m2)73±3854±2491±41<0.001
 LV mass (g)130±38122±47138±270.195
 LV mass index (g/m2)82±2378±2887±170.219
 LGE mass (g)26±1614±1138±11<0.001
 % LGE mass (%)19±1011±528±5<0.001
  • ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhancement; NYHA, New York Heart Association.